Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK

JAC Antimicrob Resist. 2021 Feb 3;3(1):dlaa114. doi: 10.1093/jacamr/dlaa114. eCollection 2021 Mar.


These evidence-based guidelines are an updated version of those issued in 2008. They have been produced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA. The guidelines update, where appropriate, previous recommendations, taking into account changes in the UK epidemiology of MRSA, ongoing national surveillance data and the efficacy of novel anti-staphylococcal agents licensed for use in the UK. Emerging therapies that have not been licensed for use in the UK at the time of the review have also been assessed.

PMID:34223066 | PMC:PMC8210269 | DOI:10.1093/jacamr/dlaa114